New biotech company Juno Therapeutics debuts with $120 mln in funding
Juno Therapeutics, a new biotechnology company focused on developing immunotherapies for cancer, has launched. Juno has raised $120 million in its initial funding. Investors include ARCH Venture Partners and the Alaska Permanent Fund, through a partnership managed by Crestline Investors. Juno has named Hans Bishop as CEO. Juno was launched by the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute.
4 December 2013•4 mins read
